Summary
A review investigates pharmacological treatments for cognitive symptoms in Alzheimer’s Disease at different phases in progression of the disease, in the context of the paucity of effective disease-modifying interventions. Discrepancies between different national and international guidelines, regarding the prescription of acetylcholinesterase inhibitors and memantine, are noted and addressed. Certain non-pharmacological treatments are also considered briefly.
Reference
Joe, E. [and] Ringman, JM. (2019). Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. BMJ. December 6th 2019; 367: l6217.
Related comment:
Full Text Link (Note: This article requires a suitable Athens password, a journal subscription or payment for access).
Reference
Walsh, S. King, E. [and] Brayne, C. (2019). France removes state funding for dementia drugs. BMJ. December 30th 2019; Vol.367: l6930.
